Director/PDMR Shareholding

RNS Number : 5148Q
GlaxoSmithKline PLC
19 February 2019
 

GlaxoSmithKline plc (the 'Company')

 

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

 

  

b)

Nature of the transaction

Transfer of 102,035 Ordinary Shares between accounts for nil consideration.

 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£0.00

102,035

 

 

 

 

 

d)

Aggregated information

n/a (single transaction)

Aggregated volume Price

 

e)

Date of the transaction

2019-02-18

f)

Place of the transaction

 

n/a

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

 

  

b)

Nature of the transaction

Transfer of 102,035 Ordinary Shares to spouse for nil consideration.

 

No change in beneficial ownership.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£0.00

102,035

 

 

 

 

 

d)

Aggregated information

n/a (single transaction)

Aggregated volume Price

 

e)

Date of the transaction

2019-02-18

f)

Place of the transaction

 

n/a

 

 

 

 

 

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr David Owen

b)

Position/status

PCA of Ms E Walmsley (Chief Executive Officer)

c)

Initial notification/

amendment

Initial Notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

 

  

b)

Nature of the transaction

Receipt of 102,035 Ordinary Shares from spouse for nil consideration.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£0.00

102,035

 

 

 

 

 

d)

Aggregated information

n/a (single transaction)

Aggregated volume Price

 

e)

Date of the transaction

2019-02-18

f)

Place of the transaction

 

n/a

 

 

 

 

 

 

 

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHZKLFFKLFLBBB

Companies

GSK (GSK)
UK 100

Latest directors dealings